New Pancreatic Cancer Study Results Reported from Fred Hutchinson Cancer Research Center
By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Pancreatic Cancer have been published. According to news reporting originating from Seattle, Washington, by NewsRx correspondents, research stated, "The highly lethal nature of pancreatic cancer and the increasing recognition of high-risk individuals have made research into chemoprevention a high priority. Here, we tested the chemopreventive activity of -tocotrienol, a bioactive vitamin E derivative extracted from palm fruit, in the LSL-Kras(G12D/);Pdx-1-Cre pancreatic cancer mouse model."
Our news editors obtained a quote from the research from Fred Hutchinson Cancer Research Center, "At 10 weeks of age, mice (n 92) were randomly allocated to three groups: (i) no treatment; (ii) vehicle and (iii) -tocotrienol (200mg/kg 2/day, PO). Treatment was continued for 12 months. Mice treated with -tocotrienol showed increased median survival from the onset of treatment (11.1 months) compared with vehicle-treated mice (9.7 months) and non-treated mice (8.5 months; P< 0.025). Importantly, none of the mice treated with -tocotrienol harbored invasive cancer compared with 10% and 8% in vehicle-treated and non-treated mice, respectively. Furthermore, -tocotrienol treatment also resulted in significant suppression of mouse pancreatic intraepithelial neoplasm (mPanIN) progression compared with vehicle-treated and non-treated mice: mPanIN-1: 4750% (P < 0.09), mPanIN-2: 611% (P < 0.001), mPanIN-3: 315% (P < 0.001) and invasive cancer: 010% (P < 0.001). -Tocotrienol treatment inhibited mutant Kras-driven pathways such as MEK/ERK, PI3K/AKT and NF-kB/p65, as well as Bcl-xL and induced p27. -Tocotrienol also induced biomarkers of apoptosis such as Bax and activated caspase 3 along with an increase in plasma levels of CK18."
According to the news editors, the research concluded: "In summary, -tocotrienols ability to interfere with oncogenic Kras pathways coupled with the observed increase in median survival and significant delay in PanIN progression highlights the chemopreventative potential of -tocotrienol and warrants further investigation of this micronutrient in individuals at high risk for pancreatic cancer."
For more information on this research see: Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-Kras(G12D/+);Pdx-1-Cre mice by vitamin E delta-tocotrienol. Carcinogenesis, 2013;34(4):858-863. Carcinogenesis can be contacted at: Oxford Univ Press, Great Clarendon St, Oxford OX2 6DP, England. (Oxford University Press - www.oup.com/; Carcinogenesis - carcin.oxfordjournals.org)
The news editors report that additional information may be obtained by contacting K. Husain, Fred Hutchinson Canc Res Center, Div Public Hlth, Seattle, WA 98109, United States (see also Pancreatic Cancer).
Keywords for this news article include: Seattle, Oncology, Treatment, Washington, United States, Gastroenterology, Pancreatic Cancer, Risk and Prevention, Pancreatic Neoplasms, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .